Literature DB >> 11429107

Trial-related discrimination in HIV vaccine clinical trials.

M Allen1, H Israel, K Rybczyk, M A Pugliese, K Loughran, L Wagner, S Erb.   

Abstract

Participants in preventive HIV vaccine trials may experience negative social consequences of trial participation, including problems related to a vaccine-induced positive HIV antibody test, yet few vaccine studies have reported on this issue. From October 1995 through November 1998, 1516 AIDS Vaccine Evaluation Group (AVEG) volunteers were assessed for reports of trial-related discrimination (TRD). Ninety TRD events were reported by 76 (5%) of 1516 volunteers. The most commonly reported incidents (n = 52, 57.8%) were negative reactions of friends, family, and co-workers to the volunteer. Few incidents (approximately 10%) were reported as linked to HIV testing. The majority of events (n = 47, 52%) were described by volunteers as "resolved" at the time of reporting, 36 (40%) as "not resolved," and for 7 (8%) events volunteers did not report resolution status. Reported incidents were analyzed by logistic regression to determine their association with the volunteer's age, sex, race, sexual orientation, and HIV risk category. There was no association between volunteer characteristics and TRD. Logistic regression and analysis of variance (ANOVA) were used to analyze association of trial sites with the number of TRD events reported. After controlling for site variation in data collection and reporting, no significant differences were found between the sites in terms of the number or type of TRD reported. Fears that TRD would be widespread and severe have not been borne out by this analysis. While the results of this study are reassuring, they should be interpreted with caution, as it is unclear whether these results may be extended to phase III trials enrolling large numbers of individuals at higher risk of HIV acquisition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429107     DOI: 10.1089/088922201750236942

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.

Authors:  Oksana Penezina; Neil X Krueger; Isaac R Rodriguez-Chavez; Michael P Busch; John Hural; Jerome H Kim; Robert J O'Connell; Eric Hunter; Said Aboud; Keith Higgins; Victor Kovalenko; David Clapham; David Crane; Andrew E Levin
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

2.  Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.

Authors:  Bret J Rudy; Bill G Kapogiannis; Michelle A Lally; Glenda E Gray; Linda-Gail Bekker; Paul Krogstad; Ian McGowan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

Review 3.  Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa.

Authors:  Joalida Smit; Keren Middelkoop; Landon Myer; Graham Lindegger; Leslie Swartz; Soraya Seedat; Tim Tucker; Robin Wood; Linda-Gail Bekker; Dan J Stein
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

4.  Exploring decision-making of HIV-infected Hispanics and African Americans participating in clinical trials.

Authors:  Migdalia V Rivera-Goba; Dinora C Dominguez; Pamela Stoll; Christine Grady; Catalina Ramos; JoAnn M Mican
Journal:  J Assoc Nurses AIDS Care       Date:  2011-01-21       Impact factor: 1.354

5.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

6.  Willingness to volunteer in a Phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Muhammad Bakari; Joachim Mwami; Eric Sandström; Asli Kulane
Journal:  Glob Health Action       Date:  2009-08-07       Impact factor: 2.640

7.  Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Authors:  Jaranit Kaewkungwal; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirasak Khamboonruang; Prayura Kunasol; Pravan Suntharasamai; Swangjai Pungpak; Sirivan Vanijanonta; Valai Bussaratid; Wirach Maek-A-Nantawat; Jittima Dhitavat; Prasert Thongcharoen; Rungrawee Pawarana; Yupa Sabmee; Mike W Benenson; Patricia Morgan; Robert J O'Connell; Jerome Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

8.  Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.

Authors:  Michele P Andrasik; Fredericka Albertina Sesay; Abby Isaacs; Linda Oseso; Mary Allen
Journal:  J Acquir Immune Defic Syndr       Date:  2020-08-15       Impact factor: 3.731

9.  Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.

Authors:  Surender Khurana; James Needham; Bonnie Mathieson; Isaac R Rodriguez-Chavez; Andrew T Catanzaro; Robert T Bailer; Jerome Kim; Vicky Polonis; David A Cooper; Jan Guerin; Michael L Peterson; Marc Gurwith; Nga Nguyen; Barney S Graham; Hana Golding
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial.

Authors:  Paula M Frew; Carlos del Rio; Lu Lu; Sarah Clifton; Mark J Mulligan
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.